Acute myeloid leukemia in a comorbid adult. About a case
DOI:
https://doi.org/10.37135/ee.004.06.06Keywords:
Acute Myeloid Leukemia, Elderly, Palliative CareAbstract
It was presented a clinical case of a male patient of 81 years of age, with a 24-hour of secondary evolution to a fall. It was characterized by drowsiness, disorientation in person, time and space, urinary incontinence and difficulty in walking, that was why a simple skull tomography was performed, in which bilateral subdural hematomas were found. The patient presented episodes of recurrent bleeding and sustained leukocytosis. Peripheral blood smear showed 28% of blasts, so a bone marrow biopsy was performed, revealing a medullary karyotype compatible with acute myeloid leukemia. The patient was classified as palliative due to its clinical characteristics and evolution. The hematological pathology above was potentially fatal. If this one was not detected early, it would generate an accelerated unfavorable evolution, especially in the elderly comorbid, as occurred in the case presented.
Downloads
References
Montaño-Figueroa E, Honorato-rosales M, Ramos-Peñafiel C, Martinez-Murillo C. Leucemia aguda mieloide en el viejo . Valoración integral y decisión terapéutica. Rev Médica del Hosp Gen México. 2010;73(4):252–7.
Bendari M, Khoubila N, Cherkaoui S, Hada N, Lamchahab M, Oukache B. Acute Myeloid Leukemia ( AML ) In Elderly : Cytogenetic Characteristics of Patients Treated At Hematology and Pediatric Oncology Center in Casablanca. Maced J Med Sci. 2018;6(12):2328–32.
Isidori A, Loscocco F, Ciciarello M, Corradi G, Lecciso M, Ocadlikova D, et al. Immunosenescence and immunotherapy in elderly acute myeloid leukemia patients: Time for a biology-driven approach. Cancers (Basel). 2018;10(211):1–12.
Lancet JE. Is the overall survival for older adults with AML finally improving? Best Pract Res Clin Haematol. 2018;31(4):387–90.
Umit EG, Baysal M, Demir AM. Frailty in patients with acute myeloid leukaemia, conceptual misapprehension of chronological age. Eur J Cancer Care (Engl). 2018;27(2):1–8.
Aguilar L, de León R, Pérez W, Montaño E, Terreros E, Martínez C, et al. Diagnóstico y Tratamiento de la Leucemia Mieloide Aguda. In: Salud CN de ET en, editor. Guía de Práctica Clínica [Internet]. México; 2010. p. 1–46. Disponible en: http://www.cenetec.salud.gob.mx/interior/gpc.html%0A
Mueller BU, Seipel K, Pabst T. Myelodysplastic syndromes and acute myeloid leukemias in the elderly. Eur J Intern Med [Internet]. Elsevier; 2018;58:28–32. Available from: https://doi.org/10.1016/j.ejim.2018.05.026
Lagunas-Rangel FA. Leucemia mieloide aguda. Una perspectiva de los mecanismos moleculares del cáncer. Gac Mex Oncol [Internet]. Sociedad Mexicana de Oncología; 2016;15(3):150–7. Available from: http://dx.doi.org/10.1016/j.gamo.2016.05.007
Leyto-Cruz F. Leucemia mieloide aguda. Rev Hematol. 2018;19(1):24–40.
Owattanapanich W, Utchariyaprasit E, Tantiworawit A, Rattarittamrong E, Niparuck P, Puavilai T, et al. Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG. Clin Lymphoma, Myeloma Leuk [Internet]. Elsevier Inc.; 2018;18(12):e509–14. Available from: https://doi.org/10.1016/j.clml.2018.08.002
Buckley S, Jimenez-Sahagun D, Othus M, Walter R, Lee S. Quality of Life from the Acute Myeloid Leukemia Patient’s Perspective. Cancer. 2018;124(1):145–52.
Finn L, Dalovisio A, Foran J. Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions. Ochsner J [Internet]. 2017;17(4):398–404. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29230125%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5718453
Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, et al. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey. Haematologica [Internet]. 2018;103(12):2040–8. Available from: http://www.haematologica.org/lookup/doi/10.3324/haematol.2018.192468
Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia. 2014;28(1):50–8.
